$8.4 M

TENX Mkt cap, 20-Sep-2018
Tenax Therapeutics Net income (Q2, 2018)3.1 M
Tenax Therapeutics Cash, 30-Jun-20183.9 M

Tenax Therapeutics Income Statement

Annual

USDFY, 2014FY, 2015FY, 2016

Revenue

158.9 k49.3 k

Revenue growth, %

(69%)(100%)

Cost of goods sold

Gross profit

R&D expense

6.5 m

General and administrative expense

3.9 m

Operating expense total

10.4 m

EBIT

(16.6 m)(14.8 m)(52.7 m)

EBIT margin, %

(10452%)(30063%)

Interest expense

2.2 m49.1 k

Income tax expense

Net Income

(19.5 m)(14.1 m)(43.9 m)

Quarterly

USDQ1, 2016Q2, 2016Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018Q2, 2018

R&D expense

1.7 m2.5 m3.9 m3.4 m3.2 m2.1 m1.2 m58.6 k369.7 k

General and administrative expense

1.4 m1.2 m1.8 m1.2 m1.3 m1.4 m1.8 m1.2 m2.7 m

Operating expense total

3.1 m3.7 m5.7 m4.7 m4.5 m3.5 m3 m1.2 m3.1 m

Interest expense

1.1 k404

Net Income

3 m3.5 m5.4 m4.6 m4.3 m3.3 m3 m1.2 m3.1 m

Tenax Therapeutics Balance Sheet

Annual

USDFY, 2014FY, 2015FY, 2016

Cash

58.3 m7.9 m10 m

Accounts Receivable

36.4 k76.5 k72.6 k

Current Assets

59 m17.5 m13.6 m

PP&E

124.4 k50.3 k19.1 k

Goodwill

11.3 m11.3 m

Total Assets

93.4 m82.9 m23.3 m

Accounts Payable

411.1 k1.2 m727.6 k

Current Liabilities

2.6 m4.5 m6.2 m

Long-term debt

346.9 k100.2 k

Total Debt

346.9 k100.2 k

Total Liabilities

6.2 m

Additional Paid-in Capital

219.5 m221.1 m221.8 m

Retained Earnings

(136.6 m)(150.7 m)(204.7 m)

Total Equity

82.9 m70.4 m17.1 m

Debt to Equity Ratio

0 x0 x

Debt to Assets Ratio

0 x0 x

Financial Leverage

1.1 x1.2 x1.4 x

Quarterly

USDQ1, 2016Q2, 2016Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018Q2, 2018

Cash

3.7 m5.1 m3.3 m1.9 m722.2 k7 m2.2 m3 m3.9 m

Accounts Receivable

98.6 k86.3 k49.3 k24.6 k72.6 k24.6 k24.6 k39.3 k39.3 k

Current Assets

21.6 m21.9 m16.1 m10.2 m7.7 m12.8 m9 m7 m6.7 m

PP&E

54.4 k42.1 k34 k29 k23.5 k18.3 k14.9 k10.5 k10.3 k

Goodwill

11.3 m11.3 m11.3 m11.3 m11.3 m

Total Assets

78.6 m75.5 m69.5 m64.1 m59.7 m19.2 m13.4 m8.3 m7 m

Accounts Payable

680.7 k521.2 k2.1 m1.5 m1.4 m1.4 m434.2 k189.6 k203.2 k

Current Liabilities

3.3 m3.6 m6.2 m5.3 m5.1 m5 m2.2 m311 k792.8 k

Long-term debt

48.4 k

Total Debt

48.4 k

Total Liabilities

11.2 m11.5 m14.2 m13.2 m13 m5 m2.2 m311 k792.8 k

Additional Paid-in Capital

221.1 m221.2 m221.4 m221.5 m221.7 m222.1 m222.2 m222.7 m222.8 m

Retained Earnings

(153.7 m)(157.2 m)(166.1 m)(170.7 m)(175 m)(207.9 m)(210.9 m)(214.7 m)(216.6 m)

Total Equity

67.4 m63.9 m55.3 m50.9 m46.7 m14.1 m11.3 m8 m6.2 m

Financial Leverage

1.2 x1.2 x1.3 x1.3 x1.3 x1.4 x1.2 x1 x1.1 x

Tenax Therapeutics Cash Flow

Annual

USDFY, 2014FY, 2015FY, 2016

Net Income

(19.5 m)(14.1 m)(10.1 m)

Depreciation and Amortization

150.5 k148.1 k31.2 k

Inventories

Cash From Operating Activities

(9.3 m)(9.7 m)(9 m)

Purchases of PP&E

(9.8 k)(4.2 k)(16.7 k)

Cash From Investing Activities

(147 k)(40.9 m)4.8 m

Cash From Financing Activities

66.9 m280.6 k(100.2 k)

Interest Paid

1.5 k

Quarterly

USDQ1, 2016Q2, 2016Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018Q2, 2018

Net Income

(3 m)(6.6 m)(5.4 m)(10 m)(14.3 m)(3.3 m)6.3 m(1.2 m)(3.1 m)

Depreciation and Amortization

12.7 k25 k4.6 k9.7 k14.5 k4 k7.5 k2.6 k5.4 k

Accounts Payable

(684.8 k)(331.9 k)

Cash From Operating Activities

(3.8 m)(6.5 m)(3.3 m)(8.5 m)(12.8 m)(4 m)(9.6 m)(1.6 m)(2.7 m)

Purchases of PP&E

(16.7 k)(16.7 k)(2.9 k)(2.9 k)(2.9 k)(3.3 k)(3.3 k)(3.1 k)(5.8 k)

Cash From Investing Activities

(380.9 k)3.8 m2.9 m6.8 m9.8 m1.1 m1.9 m2.9 m5 m

Cash From Financing Activities

(51.8 k)(100.2 k)

Interest Paid

1.1 k1.5 k

Tenax Therapeutics Ratios

USDY, 2018

Financial Leverage

1.1 x
Report incorrect company information

Tenax Therapeutics Operating Metrics

FY, 2016

Patents Issued

7

Phase III Trials Products

1

Preclinical Phase Products

1
Report incorrect company information